Muscular dystrophy, which affects approximately 250,000 people in the U.S., occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function. For years, scientists have searched for a way to successfully treat the most common form of the disease, Duchenne Muscular Dystrophy (DMD), which primarily affects boys. Now, a team of University of Missouri researchers have successfully treated dogs with DMD and say that human clinical trials are being planned in the next few years.
“This is the most common muscle disease in boys, and there is currently no effective therapy,” saidDongsheng Duan, the study leader and the Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine. “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”
Patients with Duchenne muscular dystrophy have a gene mutation that disrupts the production of a protein known as “dystrophin.” Absence of dystrophin starts a chain reaction that eventually leads to muscle cell degeneration and death. Affected boys lose their ability to walk and breathe as they get older. This places significant limitations on individuals afflicted with the disease. Dystrophin also is one of the largest genes in the human body.
“Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body,” Duan said. “Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimized dystrophin protected all muscles in the body of diseased mice.”
However, it took the team more than 10 years to develop a strategy that can safely send the micro-dystrophin to every muscle in a dog that is afflicted by the disease. The dog has a body size similar to that of an affected boy. Success in the dog will set the foundation for human tests.
In this latest study, the MU team demonstrated for the first time that a common virus can deliver the microgene to all muscles in the body of a diseased dog. The dogs were injected with the virus when they were two to three months old and just starting to show signs of DMD. The dogs are now six to seven months old and continue to develop normally.
“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” Duan said. “These dogs develop DMD naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”
The Latest on: Muscular Dystrophy
[google_news title=”” keyword=”Muscular Dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Muscular Dystrophy
- Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 3:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meetingon May 8, 2024 at 11:00 pm
The results support the best-in-class potential of KateTx's newest generation of skeletal muscle- and heart-targeted, liver de-targeted engineered MyoAAV capsids and gene regulation technology to ...
- 'He was a part of us' | Liberty Center community mourns loss of Tigers football iconon May 8, 2024 at 10:04 pm
Kent Spiess, 38, passed away on April 19 from a long battle with Duchenne Muscular Dystrophy. He routinely cheered on the Tigers from his wheelchair in the end zone.
- Regenex Bio eyes FDA meeting to confirm pivotal DMD trialon May 8, 2024 at 8:51 pm
Regenex Bio’s end of Phase II meeting with the FDA is due to take place in early Q3 2024 with hopes to initiate the pivotal trial by the end of Q3 or early Q4 2024. The Phase II dose level two from ...
- Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trialon May 8, 2024 at 10:09 am
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to ...
- Help Chattanooga firefighters 'Fill the Boot' in support of Muscular Dystrophy Associationon May 8, 2024 at 8:18 am
It’s that time of year where firefighters nationwide are joining forces to "Fill the Boot" for the Muscular Dystrophy Association.The Chattanooga Fire Departmen ...
- Child dies in gene therapy trial; Pfizer pauses studyon May 8, 2024 at 7:31 am
Death of boy in Pfizer's phase 2 study of gene therapy for Duchenne muscular dystrophy reported by patient advocacy group. Pfizer pauses dosing in another trial ...
- Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trialon May 7, 2024 at 11:19 pm
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young ...
- Young boy dies in trial for Pfizer Duchenne gene therapyon May 7, 2024 at 2:57 pm
A boy with Duchenne muscular dystrophy died after receiving a Pfizer experimental gene therapy. The company is pausing its trial in older boys.
- Pfizer Pauses Gene Therapy Trial for Muscle Disease After Deathon May 7, 2024 at 1:27 pm
Pfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who received it died suddenly.
via Bing News